All of these factors mean the time is now ripe for the biggest biotech companies to exert a positive influence on the rest of their sector. The migration of venture capitalists represents a significant opportunity for biotech's bigger players to do better by doing good. Profitable companies ought to move swiftly to fill the funding gap, leveraging their substantial resources to claim a stake in the technologies and markets of the future.
The rationale for this is straightforward. Biotech startups conflate all kinds of risks: in technology, clinical performance, market acceptance, management inexperience or ineptitude, and the possibility of being unable to attract follow-on finance. By fleeing to later-stage companies, venture capitalists reduce the risks in technology, funding and management. Corporate venturing also reduces the risks, but in a more creative manner. With their activity structured in the right way, biotech corporate ventures could provide not only streams of much-needed cash to early companies, but also biotech-specific management experience and kudos, market presence and clinical expertise. They could also reduce the risks in business development. Biogen-Idec, for example, has said that by 2010 it expects fully half of its pipeline to come from in-licensed products; most of these product deals are likely to be made with biotech startups. Likewise, corporate ventures put large biotech back in touch with grassroots science and technology, which in turn can help their core business.
It is entirely possible, of course, that none of this will happen. Large biotech firms can continue to grow their businesses, at least in the short term, by developing their internal R&D programs and simply shopping around for late-stage products. Like pharma companies before them, they might also be tempted to evergreen their patents (a subterfuge to renew an expired patent by citing a trivial new use or formulation), defend inflated prices for their drugs ($100,000 for a year's supply of Genentech's Avastin), and pay lip service to their ethics, turning a blind eye to insider trading scandals and multimillion-dollar fines for kickbacks to physicians.
But big biotech must realize that its business practices and strategy are front and center in the public eye. And its reputation affects public and investor confidence in all of biotech, big or small. That is why it is so important that large firms are seen to put something back.
The good news is that some of them are already doing it; Genentech formed GenenFUND in 2002, with MedImmune Ventures, Biogen-Idec's New Ventures and Amgen Ventures following soon after. But these funds are currently a drop in the ocean-collectively less than $500 million over the next four to five years (around 0.4% of total annual investment in the biotech sector)-and there are few signs as yet that they are aggressive in pursuing enough early ventures to make a difference.
More of biotech's profitable companies need to adopt the corporate venturing strategy. And those that are already there need to see it not as paying homage to their pasts but as an investment in their futures.
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